{"slideshow_credits": null, "snippet": "Some analysts believe that the TPG agreement undervalues Par Pharmaceutical, indicating that other suitors could surface.", "abstract": "Some analysts believe that the TPG agreement undervalues Par Pharmaceutical, indicating that other suitors could surface.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Janet", "role": "reported", "lastname": "MORRISSEY", "rank": 1, "organization": ""}], "original": "By JANET MORRISSEY"}, "web_url": "http://dealbook.nytimes.com/2012/07/16/despite-deal-with-tpg-speculation-that-par-could-garner-higher-bids/", "lead_paragraph": null, "headline": {"main": "Despite Deal With TPG, Speculation That Par Could Garner Higher Bids", "kicker": "DealBook"}, "_id": "500478ff1c22dfde670b0741", "word_count": "525", "multimedia": [], "pub_date": "2012-07-16T16:24:34Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Par Pharmaceutical Companies Inc", "rank": "1"}, {"name": "organizations", "value": "TPG Capital", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}